Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 133.13 USD 2.12% Market Closed
Market Cap: 19.5B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BIIB stock under the Base Case scenario is 200.78 USD. Compared to the current market price of 133.13 USD, Biogen Inc is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIIB Relative Value
Base Case
200.78 USD
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2
P/S
P/S
Price to Sales
2
vs History
93
vs Industry
77
Median 3Y
3.3
Median 5Y
3.2
Industry
7.1
Forward
2.1
More Details
13.2
P/E
P/E
Price to Earnings
13.2
vs History
68
vs Industry
10
Median 3Y
14.7
Median 5Y
14.5
Industry
23
Forward
8.7
More Details
7.6
P/OCF
P/OCF
Price to OCF
7.6
vs History
77
vs Industry
14
Median 3Y
18.1
Median 5Y
12
Industry
19.4
More Details
9.5
P/FCFE
P/FCFE
Price to FCFE
9.5
vs History
66
vs Industry
11
Median 3Y
28.4
Median 5Y
13.2
Industry
23.1
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
93
vs Industry
55
Median 3Y
2.4
Median 5Y
2.9
Industry
2.6
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
93
vs Industry
64
Median 3Y
3.8
Median 5Y
3.5
Industry
7.5
Forward
2.3
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
93
vs Industry
65
Median 3Y
5.1
Median 5Y
4.2
Industry
9.4
More Details
6.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.5
vs History
80
vs Industry
13
Median 3Y
11.3
Median 5Y
9.9
Industry
4.4
Forward
6.4
More Details
8.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.3
vs History
80
vs Industry
11
Median 3Y
13.1
Median 5Y
11.5
Industry
4.5
Forward
7.5
More Details
8.3
EV/OCF
EV/OCF
Enterprise Value to OCF
8.3
vs History
77
vs Industry
14
Median 3Y
19.7
Median 5Y
13.3
Industry
5.2
More Details
9.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.3
vs History
77
vs Industry
10
Median 3Y
23.9
Median 5Y
15.9
Industry
3.7
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
93
vs Industry
58
Median 3Y
1.6
Median 5Y
1.9
Industry
4.8
More Details

Multiples Across Competitors

BIIB Competitors Multiples
Biogen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Biogen Inc
NASDAQ:BIIB
19.5B USD 2 13.2 6.5 8.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 789 962.7 -165 351.5 -200 789.5 -198 498.2
US
Abbvie Inc
NYSE:ABBV
335.3B USD 5.8 80.7 15.4 22.7
US
Amgen Inc
NASDAQ:AMGN
156.1B USD 4.6 26.3 14.2 23.4
US
Gilead Sciences Inc
NASDAQ:GILD
140B USD 4.9 23.5 10.2 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.8B USD 10.4 -117.1 24.9 26.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 025 -516.7 -562.7 -547.7
AU
CSL Ltd
ASX:CSL
117.1B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53.4B USD 3.8 11.9 10.5 11.7
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.8 -64.4 -58.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.2B USD 16.7 -145.4 -650.3 -325.9
P/S Multiple
Revenue Growth P/S to Growth
US
Biogen Inc
NASDAQ:BIIB
Average P/S: 3 162 914.6
2
-1%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 789 962.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 025
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.8
4%
0.9
US
S
Seagen Inc
F:SGT
19.5
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Biogen Inc
NASDAQ:BIIB
Average P/E: 30.5
13.2
14%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 351.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.7
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -117.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -145.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Biogen Inc
NASDAQ:BIIB
Average EV/EBITDA: 14.1
6.5
2%
3.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 789.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -650.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Biogen Inc
NASDAQ:BIIB
Average EV/EBIT: 18.2
8.3
4%
2.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 498.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -325.9 N/A N/A

See Also

Summary
BIIB intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIIB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIIB stock valuation using valuation multiples.
Wall Street Estimates
BIIB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIIB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 260,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.